


BD Nexiva™ closed IV catheter system

Seamless patient care.

An integrated catheter for enhanced performance and reduction in vascular access complications.



- 1 **Success in sight.**
BD Instaflash™ needle technology provides immediate visual feedback of a successful vessel entry, reducing the number of insertion attempts required.¹ Implementation of BD Nexiva™ improved number of insertion attempts.²
- 2 **Safeguard veins with longer dwell times.**
Proprietary catheter material, BD Vialon™, supported by multiple clinical studies.^{3,4} Its unique properties allow to soften up to 70% in the vein⁵, enabling longer dwell times and reducing the chance of mechanical phlebitis by up to 50%.³
- 3 **Stabilisation.**
The built-in stabilisation platform is soft and flexible, and is designed to help minimise catheter movement in the vessel and improve catheter dwell time. Minimises movements that can lead to complications and the need to reinsert the catheter.²
- 4 **Care for the caregiver.**
Passive safety system to enclose the needle, providing protection from needlestick injury and resulting exposure.^{2,6}
- 5 **Variety of configurations to meet your preference.**
Variety of configurations to accommodate different patient needs.
- 6 **Integrated design, integrated care.**
The system features an all-in-one catheter and extension set built.

Such configuration minimises blood exposure during insertion and reduce potential for contamination.^{2,6}

Patients susceptible to vascular access complications where maximising catheter dwell time is a priority.⁷⁻⁹ Use of BD Nexiva™ allows to avoid one catheter-related complication for every eight closed systems used.⁸

1. C--1973 C--0027 Infusion Claim 2 - BD Instaflash needle technology (v0.2). 05/2020.
2. Bausone-Gazza D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter-stabilization systems. *J Infus Nurs.* 2010 Nov-Dec;33(6):371-84.
3. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral venous catheters. *Annals of Internal Medicine.* 1991 ;11 e:8e5-85e.
4. Stanley MD, Meister E, Fuschuber K. Infiltration during intravenous therapy in neonates: comparison of Teflon® and Vialon® catheters. *Southern Medical Journal.* 1992;85:883-886.
5. C--1974 C--0030 Infusion Claim 4 - BD Vialon biomaterial (v0.1). 05/2020.
6. Easterlow D, Hoddinott P, Harrison S. Implementing and standardising the use of peripheral vascular access devices. *J Clin Nurs.* 2010 Mar;19(5-6):721-7.
7. McNeill EE, Hines NL, Phariss R. A Clinical Trial of a New All-in-One Peripheral-Short Catheter. *Journal of the Association for Vascular Access.* Volume 14, Issue 1, 2009, Pages 46-51.
8. Gonzalez Lopez JL, Vilela AA, del Palacio EF. Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. *J Hosp Infect.* 2014;86(2):117-126.
9. Tamura N, Abe S, Hagimoto K, et al. Unfavorable peripheral intravenous catheter replacements can be reduced using an integrated closed intravenous catheter system. *J Vase Access.* 2014;15(4):257-263.

BD Switzerland Särl, Terre Bonne Park – A4 Route de Crassier 17, 1262 Eysins, Switzerland

bd.com